Skip to content
Biosplice Therapeutics logo — Restore health by delivering first-in-class therapies that h...

Biosplice Therapeutics

Restore health by delivering first-in-class therapies that harness alternative splicing

Founded 2008 United States San Diego, United States 37 employees Grant Total: $778.00M Biotechnology, Health Care +1

General Information

Company Name Biosplice Therapeutics
Founded Year 2008
Location United States San Diego, United States
Employees 37
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Biosplice Therapeutics. To contact Biosplice Therapeutics, visit biosplice.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Biosplice Therapeutics compare?

A PDF of Biosplice Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Biosplice Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Biosplice Therapeutics

Biosplice Therapeutics, founded in 2008 and headquartered in the United States, is dedicated to restoring health by delivering pioneering therapies that leverage alternative splicing. The company's focus on small-molecule therapeutics, rooted in the groundbreaking science of alternative pre-mRNA splicing, has led to the development of drugs like lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for various cancers, and a diverse pipeline encompassing conditions from Alzheimer’s disease to other degenerative ailments. Driven by its discoveries in Wnt pathway modulation, Biosplice has unveiled the groundbreaking biology connecting CLK/DYRK kinases to the therapeutic control of alternative splicing. This mechanism, vital for regulating protein diversification within cells and thus determining cell type and function, presents promising druggable targets within the cellular "command and control" center. The latest investment, a grant received on 08 March 2024, was provided by CDMRP. Biosplice's innovative approach to leveraging alternative splicing for therapeutic benefits positions it at the forefront of the Biotechnology, Health Care, and Life Sciences industries. To explore more about Biosplice Therapeutics and its pioneering work in alternative splicing therapies, visit www.biosplice.com.

Business keywords: Medical Research, Therapeutics Development, Regenerative Medicine, Oncology, Degenerative Diseases, Alternative Splicing, Wnt Pathway Modulation, Small Molecule Therapeutics, Clinical Development, Tissue-Level Regeneration, Alzheimer's Disease, Pre-mRNA Splicing, CLK/DYRK Kinases, Regenerative Pathways

Services & Products

Therapeutic Modulation of Alternative Splicing

Target Customers

Patients with Osteoarthritis Cancer Neurological Disorders and Diabetes

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
CDMRP
08 Mar 2024
Venture Round $120.00M 5
Sands Capital Ventures, Verition Fund Management +3
15 Apr 2021
Series C Undisclosed 1
Cem Ortabaş
01 Apr 2019
Series B $438.00M 3
Vickers Venture Partners, Swicorp +1
06 Aug 2018
Series A $220.00M 3
Vickers Venture Partners, Polar Light Ventures +1
01 Sep 2013
Seed Round Undisclosed 1
Esas Ventures
01 Sep 2012

Biosplice Therapeutics Alternatives & Competitors

View All Alternatives
Biosplice Therapeutics vs
CK Regeon
CK Regeon Korea South

CK Regeon Inc. is a biotechnology-based company aiming to develop First-In-Class drugs with clear MO...

Series B
9 employees
Biotechnology, Health Care
Biosplice Therapeutics vs
Surrozen
Surrozen United States

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicin...

67 employees
Biotechnology, Health Care
Biosplice Therapeutics vs

Advancing Accessible Solutions for Complex Neurodegenerative Diseases

IPO
29 employees
Biotechnology, Health Care

FAQ About Biosplice Therapeutics

Restore health by delivering first-in-class therapies that harness alternative splicing
Biosplice Therapeutics was founded in 2008.
Biosplice Therapeutics is headquartered in San Diego, United States.
Biosplice Therapeutics operates in Biotechnology, Health Care and Life Sciences. Its work centres on Medical Research, Therapeutics Development, Regenerative Medicine and Oncology. Its customers include Patients with Osteoarthritis, Cancer and Neurological Disorders.
Biosplice Therapeutics has approximately 37 employees.
Biosplice Therapeutics has completed 6 funding rounds, raising a total of $778.00M. The latest funding stage is Grant.
Biosplice Therapeutics offers: Therapeutic Modulation of Alternative Splicing.
Top alternatives and competitors to Biosplice Therapeutics include CK Regeon, Surrozen, Cognition Therapeutics, Inc., AgeX Therapeutics, Inc. , Notogen Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Biosplice Therapeutics and CK Regeon are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Biosplice Therapeutics, https://bouncewatch.com/company/samumed, updated 24 March 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout